Clinical trial
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate…
NCT00146211 · Amarin Neuroscience Ltd, Industry · Completed
Key facts
| NCT number | NCT00146211 |
|---|---|
| Title | TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease |
| Official title | A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease |
| Lead sponsor | Amarin Neuroscience Ltd, Industry |
| Collaborators | Huntington Study Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Huntington Disease |
| Intervention type | Drug |
| Interventions | Ethyl-EPA (Miraxion™) |
| Enrollment | 300 |
| Start date | Sep 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 7, 2005 |
| Last update posted | Dec 27, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: